Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

ISC Konstanz has partnered with Celloraa Energy to develop a 1.2GW TOPCon cell production facility in Gujarat, India.

The cell therapy manufacturing market offers significant opportunities driven by technological advancements, increasing ...

The "Cell and Gene Therapy Manufacturing Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report ...

Johnson & Johnson on Wednesday announced plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be ...

Pennsylvania Gov. Josh Shapiro said Feb. 18 the state secured an over $1 billion investment from New Brunswick-headquartered Johnson & Johnson to build a next-generation cell therapy manufacturing ...

Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...

Add Yahoo as a preferred source to see more of our stories on Google. GREENVILLE, N.C. (WNCT) — A solar energy technology company has finished the exterior construction on a new cell manufacturing ...

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

RENA Technologies will supply its equipment to a planned 1.2GW TOPCon solar cell production facility in India.